SAN DIEGO, CA – February 19, 2024 - Antharis Therapeutics, a leader in the development of innovative, next-generationbiotherapeutics, is proud to announce that it has been recognized as the “Biopharmaceutical Company of the Year 2024 - California” by the prestigious Global Health & Pharma Biotechnology Awards. This accolade highlights Antharis’ commitment to advancing cancer treatment through the development of cutting-edge monoclonal antibodies and antibody-drug conjugates (ADCs).
The award celebrates Antharis’ pioneering efforts in oncology, in particular exploiting mechanisms that harness the power of the immune system to tackle unmet medical needs. Antharis’ CEO and Chairman, Dr. Raphael Ribeiro-Pinaud, PhD, MBA, emphasized the company’s focus on delivering transformative and innovative solutions, to push the boundaries of oncology treatment.
“We are honored to receive this award, which reflects the dedication of our team and our mission to bring advanced therapies to patients who need them most. Our monoclonal antibody program is designed to provide new hope for those facing devastating diseases, and we remain committed to developing innovative, effective and accessible treatments to patients in need, worldwide”, said Dr. Ribeiro-Pinaud.
To learn more about Antharis Therapeutics’ journey and groundbreaking work, read the full feature in the upcoming GHP Biotechnology Awards article here.
About Antharis Therapeutics
Antharis Therapeutics is a leading biopharmaceutical company focused on developing monoclonal antibody therapies for oncology and other critical medical fields. The company’s innovative approach to cancer treatment harnesses the power of immuno-oncology, enhancing the body’s immune response to fight cancer effectively. With a robust pipeline of therapies and a multidisciplinary team of experts, Antharis is dedicated to transforming the future of healthcare by delivering safe, effective, and life-changing treatments to patients worldwide. For more information, please visit www.antharistherapeutics.com.
